Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F-18 florbetapir in cardiac amyloidosis
NCT03040427Phase 4Terminated
- Sponsor
- Cleveland Clinic
- Start
- Jan 2017
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of Florbetapir in cardiac amyloidosis, sponsored by Cleveland Clinic. Started Jan 2017; status: terminated.
02
Drugs
Florbetapir
03
Conditions
cardiac amyloidosis
Beyond the preview
Go deeper on NCT03040427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03040427.